Overview
BioMaxima S.A. is a Polish, Warsaw Stock Exchange-listed manufacturer of microbiological media, reagents and in vitro diagnostics equipment. The company provides microbiology, molecular diagnostics and cell culture products, laboratory diagnostics and disposable materials. It also runs training courses for laboratories, including validation and verification of microbiological test methods and Legionella diagnostics.
Financials
Revenue history (in m)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Stock quotes
- Open
- PLN 9.94
- High
- PLN 9.94
- Low
- PLN 9.90
- Volume
- 712
- Avg. vol.
- 2.99K
- Market cap
- PLN 41.68M
- P/E ratio
- 52.32
- EPS
- PLN 0.19
- Shares outstanding
- 4.19M
- 52-week
- PLN 9.88 – 10.16
- Dividend yield
- 5.03%
- Dividend
- PLN 0.50
- Ex dividend date
- Jun 16, 2023
- ISIN
- PLBIOMX00015
- Exchange
- GPW Main Market
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD 3.75m | USD 207.73k | USD 97.78k |
| Q1 2026 | USD 4.27m | USD 146.14k | USD 88.60k |
| Q4 2025 | USD 4.33m | USD 197.64k | USD 106.23k |
| Q3 2025 | USD 3.51m | USD -5.78k | USD -76.34k |
Results for Q3 2026:Nov 30, 2026
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2002-09-16. Active
91 1160 2202 0000 0000 8606 5811
79 1050 1953 1000 0090 3132 2168- 85 1160 2202 0000 0003 4504 3406
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Jan 26, 2011 | Merger plan |
Public aid
44 public aid cases recorded, with a total value of $4,945,134.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 25, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $14,675$14,675 | Prezes Banku Gospodarstwa Krajowego | |
| Jun 25, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $11,217$11,217 | Prezes Banku Gospodarstwa Krajowego | |
| Jun 25, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $9,581$9,581 | Prezes Banku Gospodarstwa Krajowego |
European Funds
20 projects co-financed from European Funds recorded, with total EU co-financing of $5,635,659.
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2026-07-01 | Wdrożenie wyników prac B+R w Biomaxima nad nowymi gradientowymi testami paskowymi MIC | $259.8K$259,789 | Fundusze Europejskie dla Lubelskiego 2021-2027 | |
| 2025-11-02 | Promocja produktów Biomaxima poprzez udział w targach zagranicznych | $70,856$70,856 | Fundusze Europejskie dla Lubelskiego 2021-2027 | |
| 2025-10-01 | Zwiększenie konkurencyjności Biomaxima poprzez wdrożenie wyników prac B+R nad nowymi bibułowymi krążkami antybiotykowymi | $275.7K$275,699 | Fundusze Europejskie dla Lubelskiego 2021-2027 |
Tenders
979 tenders recorded as contractor: 702 national ($8,779,582) and 277 EU ($120,886,323).
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Sep 29, 2026 | Postępowanie o udzielenie zamówienia publicznego w trybie przetargu nieograniczonego na dostawę odczynników i drobnego sprzętu na potrzeby Zakładu Diagnostyki Laboratoryjnej | —— | Uniwersytecki Szpital Dziecięcy w Lublinie | |
| Sep 28, 2026 | Dostawa odczynników i sprzętu laboratoryjnego II | —— | Zespół Opieki Zdrowotnej w Oławie | |
| Sep 21, 2026 | Dostawa odczynników i materiałów zużywalnych do wykonywania badań analitycznych wraz z dzierżawą analizatorów | —— | 1 Wojskowy Szpital Kliniczny z Polikliniką Samodzielny Publiczny Zakład Opieki Zdrowotnej w Lublinie |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
In the case of a multi-member management board, the joint action of two members of the management board or of one member of the management board jointly with a commercial proxy is required to submit declarations and to sign on behalf of the company.
Supervisory board
Beneficial owners
No beneficial owners recorded for the company Biomaxima.
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Techmotsp. z o.o. | $7,176,732.37 | tech-mot.pl | ||
| Nanomaxsp. z o.o. | $1,764,224.34 | nanomax.pl |
Change history
| Date | Event | |
|---|---|---|
| 2023-09-01 | Share capital change (4,373,305.00 PLN → 4,193,118.00 PLN) | |
| 2023-04-05 | Share capital change (4,328,500.00 PLN → 4,373,305.00 PLN) | |
| 2022-03-31 | Share capital change (4,320,000.00 PLN → 4,328,500.00 PLN) | |
| 2021-02-26 | Share capital change (4,210,000.00 PLN → 4,320,000.00 PLN) | |
| 2020-04-28 | Share capital change (3,730,000.00 PLN → 4,210,000.00 PLN) |
FAQ
Last updated: 2026-06-19